PROGNOSTIC VALUE OF CLINICAL AND MORPHOLOGICAL FACTORS OF BREAS T CANCER IN REAL CLINICAL PRACTICE
https://doi.org/10.24412/2790-1289-2023-1-21-27
Abstract
In this article, we present the material of a retrospective analysis of the frequency of occurrence and prognostic role of certain morphological markers (tumor infiltrating lymphocytes (TILs), tumor emboli in the walls of vessels, invasion into the walls of vessels) in patients with a newly diagnosed breast cancer (breast cancer) who received treatment in the conditions of the Almaty regional Multidisciplinary Clinic (ARMK), depending on the age, stage of the disease and the phenotype of the tumor.
About the Authors
S. Yessentayeva
NEI «Kazakh-Russian Medical University»
Kazakhstan
Kazakhstan
Yessentayeva Suriya, MD, Associate Professor
Almaty
A. Abylgazieva
NEI «Kazakh-Russian Medical University»
Kazakhstan
Kazakhstan
Aidana Abylgazieva
Almaty
D. Aidarov
NEI «Kazakh-Russian Medical University»
Kazakhstan
Kazakhstan
Daulet Aidarov
Almaty
G. Sarsenbayeva
NEI «Kazakh-Russian Medical University»
Kazakhstan
Kazakhstan
Galiya Sarsenbayeva
Almaty
E. Beisebaev
NEI «Kazakh-Russian Medical University»
Kazakhstan
Kazakhstan
Eldar Beisebaev
Almaty
References
1. Kiselevskiy M.V., Vlasenko R.Ya., Zabotina T.N., Kadagidze Z.G. Prognostic significance of tumor-infiltrating lymphocytes. Immunology. 2019; 40 (1): 74–83. doi: 10.24411/0206-4952-2019-11009.
2. Semiglazov V.F., Tseluyko A.I., Donskikh R.V. et al. Immunology and immunotherapy of breast cancer // Effective pharmacotherapy. 2020. T. 16. № 11. S. 46–51. DOI 10.33978/2307-3586-2020-16-11-46-51.
3. Semiglazov V.F., Krivorot'ko P.V., Semiglazov V.V. et al. Immunology of breast cancer. M.: SIMK, 2019.
4. Denkert C., Loibl S., Noske A., Roller M., Muller B.M., Komor M., Budczies J., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010; 28 (1):105-113. https//doi.org/10.1200/JCO.2009.23.7370.
5. Denkert C., von Mickwitz G., Brafе J. et al. Tumorinfiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers // J. Clin. Oncol. 2015. Vol. 33. № 9. P. 983 – 991.
6. Dieci M.V., Mathieu M.C., Guarneri V. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials // Ann. Oncol. 2015. Vol. 26. № 8. P. 1698 – 1704.
7. Loi S., Michiels S., Salgado R. et al. Tumor-infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial // Ann. Oncol. 2014. Vol. 25. № 8. P. 1544–1550
8. Smirnova O.V., Borisov V.I. Borisov V.I. Immunotherapy in the drug treatment of patients with metastatic triple negative breast cancer. Oncology. Magazine named after P.A. Gertsena. 2018; 7(6):60 66.
9. Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node - positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02 - 98. J. Clin. Oncol. 2013; 31 (7): 860-867. https//doi.org/10.1200/JCO.2011.41.0902.
10. Adams S., Gray R.J., Demaria S., Goldstein L., Perez E.A., Shulman L.N., et al. Prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J.Clin. Oncol. 2014; 32 (27): 2959 - 2966. https//doi.org/10.1200/JCO.2013.55.0491.
11. Disis M.L., Stanton S.E. Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am. Soc. Clin. Oncol. Educ. Book. 2015:e25 - 30. doi: 10.14694/EdBook_AM.2015.35.e25. PMID: 25993181.
12. Smid M., Hoes M., Sieuwerts A.M. et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes // Breast Cancer Res. Treat. 2011. Vol. 128. № 1. P. 23 – 30.
Review
For citations:
Yessentayeva S., Abylgazieva A., Aidarov D., Sarsenbayeva G., Beisebaev E. PROGNOSTIC VALUE OF CLINICAL AND MORPHOLOGICAL FACTORS OF BREAS T CANCER IN REAL CLINICAL PRACTICE. Actual Problems of Theoretical and Clinical Medicine. 2023;(1):21-27. (In Russ.) https://doi.org/10.24412/2790-1289-2023-1-21-27
Views:
252
